<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>GLP-1 Medication Comparison ‚Äî Ozempic vs Wegovy vs Mounjaro vs Zepbound</title>
    <meta name="description" content="Compare all GLP-1 agonists head-to-head: Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity. Weight loss, A1C reduction, side effects, cost, and clinical trial data.">
    <link rel="canonical" href="https://glp1.md/comparison.html">
    
    <!-- AI Meta Tags -->
    <meta name="ai-content" content="evidence-based health information">
    <meta name="ai-training" content="allowed">
    <meta name="ai-topic" content="GLP-1 comparison, Ozempic vs Mounjaro, weight loss medications">
    <meta name="ai-audience" content="patients, caregivers, healthcare providers">
    <meta name="ai-use" content="education, research, clinical support">
    
    <link rel="icon" type="image/svg+xml" href="data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 32 32'%3E%3Ctext x='16' y='24' font-family='-apple-system,system-ui,sans-serif' font-weight='800' font-size='16' fill='%230d9488' text-anchor='middle' letter-spacing='-0.5'%3E.md%3C/text%3E%3C/svg%3E">
    <link href="https://fonts.googleapis.com/css2?family=Source+Serif+4:wght@400;500;600;700&family=Inter:wght@400;500;600&display=swap" rel="stylesheet">
    <style>
        :root {
            --bg-primary: #ffffff;
            --bg-secondary: #f8fafc;
            --bg-tertiary: #f1f5f9;
            --text-primary: #0f172a;
            --text-secondary: #475569;
            --text-muted: #94a3b8;
            --accent: #0d9488;
            --accent-dark: #0f766e;
            --accent-light: #ccfbf1;
            --border: #e2e8f0;
            --font-display: 'Source Serif 4', Georgia, serif;
            --font-body: 'Inter', -apple-system, sans-serif;
        }
        * { margin: 0; padding: 0; box-sizing: border-box; }
        body {
            font-family: var(--font-body);
            background: var(--bg-primary);
            color: var(--text-primary);
            line-height: 1.7;
            font-size: 16px;
        }
        header {
            position: fixed;
            top: 0;
            left: 0;
            right: 0;
            z-index: 100;
            background: rgba(255, 255, 255, 0.95);
            backdrop-filter: blur(10px);
            border-bottom: 1px solid var(--border);
        }
        .header-inner {
            max-width: 1100px;
            margin: 0 auto;
            padding: 16px 24px;
            display: flex;
            justify-content: space-between;
            align-items: center;
        }
        .logo {
            font-family: var(--font-display);
            font-size: 22px;
            font-weight: 600;
            color: var(--text-primary);
            text-decoration: none;
        }
        .logo span { color: var(--accent); }
        nav { display: flex; gap: 32px; }
        nav a {
            color: var(--text-secondary);
            text-decoration: none;
            font-size: 14px;
            font-weight: 500;
            transition: color 0.2s;
        }
        nav a:hover { color: var(--accent); }
        main {
            max-width: 900px;
            margin: 0 auto;
            padding: 120px 24px 64px;
        }
        .page-header {
            margin-bottom: 48px;
        }
        .page-eyebrow {
            font-size: 13px;
            font-weight: 600;
            color: var(--accent);
            text-transform: uppercase;
            letter-spacing: 1px;
            margin-bottom: 12px;
        }
        h1 {
            font-family: var(--font-display);
            font-size: clamp(32px, 5vw, 42px);
            font-weight: 700;
            line-height: 1.2;
            margin-bottom: 16px;
            color: var(--text-primary);
        }
        .page-subtitle {
            font-size: 18px;
            color: var(--text-secondary);
            line-height: 1.6;
        }
        .section {
            margin-bottom: 48px;
        }
        h2 {
            font-family: var(--font-display);
            font-size: 26px;
            font-weight: 700;
            margin-bottom: 16px;
            color: var(--text-primary);
        }
        h3 {
            font-family: var(--font-display);
            font-size: 19px;
            font-weight: 600;
            margin: 24px 0 12px;
            color: var(--text-primary);
        }
        p {
            font-size: 17px;
            color: var(--text-secondary);
            margin-bottom: 16px;
            line-height: 1.7;
        }
        .comparison-table {
            width: 100%;
            border-collapse: collapse;
            margin: 24px 0;
            border: 1px solid var(--border);
            border-radius: 8px;
            overflow: hidden;
        }
        .comparison-table thead {
            background: var(--bg-secondary);
        }
        .comparison-table th {
            padding: 12px 16px;
            text-align: left;
            font-size: 13px;
            font-weight: 600;
            color: var(--text-primary);
            border-bottom: 1px solid var(--border);
        }
        .comparison-table td {
            padding: 12px 16px;
            font-size: 14px;
            color: var(--text-secondary);
            border-bottom: 1px solid var(--border);
        }
        .comparison-table tr:last-child td {
            border-bottom: none;
        }
        .comparison-table tr:hover {
            background: var(--bg-secondary);
        }
        .highlight {
            background: var(--accent-light);
            font-weight: 600;
            color: var(--accent-dark);
        }
        .info-box {
            background: var(--bg-secondary);
            border: 1px solid var(--border);
            border-left: 4px solid var(--accent);
            border-radius: 8px;
            padding: 20px;
            margin: 24px 0;
        }
        .info-box h3 {
            margin-top: 0;
            font-size: 17px;
        }
        .info-box p {
            margin-bottom: 0;
            font-size: 15px;
        }
        ul, ol {
            margin-left: 24px;
            margin-bottom: 16px;
            color: var(--text-secondary);
            line-height: 1.8;
        }
        li { margin-bottom: 8px; }
        footer {
            background: var(--bg-secondary);
            border-top: 1px solid var(--border);
            padding: 48px 24px;
            margin-top: 80px;
        }
        .footer-inner {
            max-width: 1100px;
            margin: 0 auto;
            text-align: center;
            font-size: 14px;
            color: var(--text-muted);
        }
        .table-note {
            font-size: 13px;
            color: var(--text-muted);
            margin-top: 12px;
        }
        @media (max-width: 768px) {
            nav { display: none; }
            main { padding: 100px 16px 40px; }
            .comparison-table { font-size: 11px; }
            .comparison-table th, .comparison-table td { padding: 8px 6px; }
        }
    
        /* Medical Reviewer Badge */
        .medical-reviewer { display: flex; align-items: center; gap: 0.4rem; margin-top: 0.75rem; padding: 0.5rem 0.75rem; background: #f0fdfa; border: 1px solid #ccfbf1; border-radius: 6px; font-size: 0.8rem; color: #0f766e; width: fit-content; }
        .medical-reviewer svg { flex-shrink: 0; }
        .medical-disclaimer { font-size: 0.75rem; color: var(--text-muted, #94a3b8); margin-top: 2rem; padding-top: 1rem; border-top: 1px solid var(--border, #e2e8f0); }
    </style>

    <script type="application/ld+json">
    {
  "@context": "https://schema.org",
  "@type": "BreadcrumbList",
  "itemListElement": [
    {
      "@type": "ListItem",
      "position": 1,
      "name": "glp1.md",
      "item": "https://glp1.md/"
    },
    {
      "@type": "ListItem",
      "position": 2,
      "name": "GLP-1 Medication Comparison \u2014 Ozempic vs Wegovy vs Mounjaro vs Zepbound"
    }
  ]
}
    </script>

    <script type="application/ld+json">
    {
  "@context": "https://schema.org",
  "@type": "MedicalWebPage",
  "name": "GLP-1 Medication Comparison \u2014 Ozempic vs Wegovy vs Mounjaro vs Zepbound",
  "description": "Compare all GLP-1 agonists head-to-head: Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity. Weight loss, A1C reduction, side effects, cost, and clinical trial data.",
  "url": "https://glp1.md/comparison.html",
  "publisher": {
    "@type": "Organization",
    "name": "thrive.md Editorial Team",
    "url": "https://thrive.md"
  },
  "isPartOf": {
    "@type": "WebSite",
    "name": "glp1.md",
    "url": "https://glp1.md/"
  }
}
    </script>
</head>
<body>
    <header>
        <div class="header-inner">
            <a href="/" class="logo">glp1<span>.md</span></a>
            <nav>
                <a href="/">Home</a>
                <a href="/comparison.html">Compare Meds</a>
                <a href="/side-effects.html">Side Effects</a>
                <a href="/cost-insurance.html">Cost & Insurance</a>
                <a href="/eligibility.html">Who Qualifies</a>
                <a href="/faq.html">FAQ</a>
            </nav>
        </div>
    </header>

    <main>
        <div class="page-header">
            <div class="page-eyebrow">Medication Comparison</div>
            <h1>GLP-1 Medications Compared</h1>
            <p class="page-subtitle">Head-to-head comparison of all FDA-approved GLP-1 receptor agonists. Data from clinical trials and FDA-approved prescribing information.</p>
        </div>

        <section class="section">
            <h2>Complete Comparison Table</h2>
            <table class="comparison-table">
                <thead>
                    <tr>
                        <th>Medication</th>
                        <th>Generic</th>
                        <th>Indication</th>
                        <th>Frequency</th>
                        <th>Max Dose</th>
                        <th>A1C ‚Üì</th>
                        <th>Weight Loss</th>
                        <th>Cost/Month</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Ozempic</strong></td>
                        <td>Semaglutide</td>
                        <td>Diabetes</td>
                        <td>Weekly</td>
                        <td>2 mg</td>
                        <td>1.5-1.8%</td>
                        <td>12-14 lbs</td>
                        <td>$935</td>
                    </tr>
                    <tr>
                        <td><strong>Wegovy</strong></td>
                        <td>Semaglutide</td>
                        <td>Weight Loss</td>
                        <td>Weekly</td>
                        <td>2.4 mg</td>
                        <td>1.5%</td>
                        <td class="highlight">15-17%</td>
                        <td>$1,349</td>
                    </tr>
                    <tr>
                        <td><strong>Mounjaro</strong></td>
                        <td>Tirzepatide</td>
                        <td>Diabetes</td>
                        <td>Weekly</td>
                        <td>15 mg</td>
                        <td class="highlight">2.0-2.5%</td>
                        <td>15-25 lbs</td>
                        <td>$1,023</td>
                    </tr>
                    <tr>
                        <td><strong>Zepbound</strong></td>
                        <td>Tirzepatide</td>
                        <td>Weight Loss</td>
                        <td>Weekly</td>
                        <td>15 mg</td>
                        <td>2.0%</td>
                        <td class="highlight">20-22%</td>
                        <td>$1,060</td>
                    </tr>
                    <tr>
                        <td><strong>Trulicity</strong></td>
                        <td>Dulaglutide</td>
                        <td>Diabetes</td>
                        <td>Weekly</td>
                        <td>4.5 mg</td>
                        <td>1.0-1.5%</td>
                        <td>4-8 lbs</td>
                        <td>$970</td>
                    </tr>
                    <tr>
                        <td><strong>Rybelsus</strong></td>
                        <td>Semaglutide</td>
                        <td>Diabetes</td>
                        <td>Daily (oral)</td>
                        <td>14 mg</td>
                        <td>1.0-1.4%</td>
                        <td>6-10 lbs</td>
                        <td>$935</td>
                    </tr>
                    <tr>
                        <td><strong>Victoza</strong></td>
                        <td>Liraglutide</td>
                        <td>Diabetes</td>
                        <td>Daily</td>
                        <td>1.8 mg</td>
                        <td>1.0-1.5%</td>
                        <td>6-10 lbs</td>
                        <td>$987</td>
                    </tr>
                    <tr>
                        <td><strong>Saxenda</strong></td>
                        <td>Liraglutide</td>
                        <td>Weight Loss</td>
                        <td>Daily</td>
                        <td>3.0 mg</td>
                        <td>0.5-1.0%</td>
                        <td>8-10%</td>
                        <td>$1,350</td>
                    </tr>
                </tbody>
            </table>
            <p class="table-note">Prices are average cash prices without insurance from GoodRx (February 2026). Weight loss shown as lbs for diabetes trials, % of body weight for obesity trials. Individual results vary significantly.</p>
        </section>

        <section class="section">
            <h2>Ozempic vs Mounjaro (Semaglutide vs Tirzepatide)</h2>
            <p>The two most popular GLP-1 medications compared:</p>
            
            <table class="comparison-table">
                <thead>
                    <tr>
                        <th>Factor</th>
                        <th>Ozempic</th>
                        <th>Mounjaro</th>
                        <th>Winner</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>A1C Reduction</strong></td>
                        <td>1.5-1.8%</td>
                        <td>2.0-2.5%</td>
                        <td class="highlight">Mounjaro</td>
                    </tr>
                    <tr>
                        <td><strong>Weight Loss</strong></td>
                        <td>12-14 lbs</td>
                        <td>15-25 lbs</td>
                        <td class="highlight">Mounjaro</td>
                    </tr>
                    <tr>
                        <td><strong>CV Outcomes Data</strong></td>
                        <td>SUSTAIN 6 (positive)</td>
                        <td>Trials ongoing</td>
                        <td class="highlight">Ozempic</td>
                    </tr>
                    <tr>
                        <td><strong>Time on Market</strong></td>
                        <td>Since 2017</td>
                        <td>Since 2022</td>
                        <td>Ozempic</td>
                    </tr>
                    <tr>
                        <td><strong>GI Side Effects</strong></td>
                        <td>Common</td>
                        <td>Slightly more common</td>
                        <td>Similar</td>
                    </tr>
                    <tr>
                        <td><strong>Insurance Coverage</strong></td>
                        <td>Widely covered</td>
                        <td>Increasingly covered</td>
                        <td>Ozempic</td>
                    </tr>
                </tbody>
            </table>
            
            <div class="info-box">
                <h3>üí° Key Difference: Dual vs Single Agonist</h3>
                <p>Mounjaro/Zepbound are dual GIP/GLP-1 agonists, targeting two incretin receptors instead of one. This may explain their superior efficacy for blood sugar control and weight loss. However, Ozempic has longer-term safety data and proven cardiovascular benefits from the SUSTAIN 6 trial.</p>
            </div>
        </section>

        <section class="section">
            <h2>Wegovy vs Zepbound (For Weight Loss)</h2>
            <p>Comparing the two FDA-approved GLP-1 options for chronic weight management:</p>
            
            <table class="comparison-table">
                <thead>
                    <tr>
                        <th>Factor</th>
                        <th>Wegovy</th>
                        <th>Zepbound</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Average Weight Loss</strong></td>
                        <td>15-17% of body weight</td>
                        <td class="highlight">20-22% of body weight</td>
                    </tr>
                    <tr>
                        <td><strong>Patients losing ‚â•20%</strong></td>
                        <td>~35%</td>
                        <td class="highlight">~60%</td>
                    </tr>
                    <tr>
                        <td><strong>CV Outcomes Data</strong></td>
                        <td class="highlight">SELECT trial: 20% MACE reduction</td>
                        <td>Trials ongoing</td>
                    </tr>
                    <tr>
                        <td><strong>Nausea Rate</strong></td>
                        <td>44%</td>
                        <td>~30%</td>
                    </tr>
                    <tr>
                        <td><strong>Monthly Cost</strong></td>
                        <td>$1,349</td>
                        <td>$1,060</td>
                    </tr>
                    <tr>
                        <td><strong>Adolescent Approval</strong></td>
                        <td class="highlight">Yes (12+)</td>
                        <td>No</td>
                    </tr>
                </tbody>
            </table>
            
            <p><strong>Bottom line:</strong> Zepbound produces more weight loss on average, but Wegovy has landmark cardiovascular outcomes data from the SELECT trial showing a 20% reduction in heart attacks, strokes, and cardiovascular death in patients with obesity but without diabetes.</p>
        </section>

        <section class="section">
            <h2>Side Effect Comparison</h2>
            <p>All GLP-1 medications share similar GI side effects. Here's how they compare:</p>
            
            <table class="comparison-table">
                <thead>
                    <tr>
                        <th>Side Effect</th>
                        <th>Ozempic</th>
                        <th>Wegovy</th>
                        <th>Mounjaro</th>
                        <th>Zepbound</th>
                        <th>Trulicity</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Nausea</strong></td>
                        <td>15-20%</td>
                        <td>44%</td>
                        <td>12-18%</td>
                        <td>24-33%</td>
                        <td>12%</td>
                    </tr>
                    <tr>
                        <td><strong>Diarrhea</strong></td>
                        <td>9%</td>
                        <td>30%</td>
                        <td>12-17%</td>
                        <td>18-21%</td>
                        <td>9%</td>
                    </tr>
                    <tr>
                        <td><strong>Vomiting</strong></td>
                        <td>9%</td>
                        <td>24%</td>
                        <td>5-9%</td>
                        <td>9-12%</td>
                        <td>6%</td>
                    </tr>
                    <tr>
                        <td><strong>Constipation</strong></td>
                        <td>5%</td>
                        <td>24%</td>
                        <td>6-7%</td>
                        <td>6-10%</td>
                        <td>5%</td>
                    </tr>
                </tbody>
            </table>
            <p class="table-note">Higher doses (used for weight loss) generally have higher side effect rates than diabetes doses. Side effects typically improve over 4-8 weeks.</p>
        </section>

        <section class="section">
            <h2>Which GLP-1 is Right for You?</h2>
            
            <h3>Best for Type 2 Diabetes with CV Risk</h3>
            <p><strong>Ozempic</strong> ‚Äî Proven cardiovascular benefit (SUSTAIN 6), longest track record, widely covered by insurance.</p>
            
            <h3>Best for Type 2 Diabetes Needing Maximum A1C Control</h3>
            <p><strong>Mounjaro</strong> ‚Äî Highest A1C reduction in the class (up to 2.5%), also significant weight loss.</p>
            
            <h3>Best for Weight Loss (Obesity)</h3>
            <p><strong>Zepbound</strong> ‚Äî Highest weight loss in trials (20-22%), though Wegovy has cardiovascular outcomes data.</p>
            
            <h3>Best for Needle-Averse Patients</h3>
            <p><strong>Rybelsus</strong> ‚Äî Only oral GLP-1 option, though requires strict dosing (empty stomach, 30 min before food/drink).</p>
            
            <h3>Best Established Option</h3>
            <p><strong>Trulicity</strong> ‚Äî On market since 2014, good tolerability, moderate efficacy, well-studied.</p>
            
            <div class="info-box">
                <h3>‚öïÔ∏è Talk to Your Doctor</h3>
                <p>This comparison is for educational purposes only. The best GLP-1 medication for you depends on your specific medical history, insurance coverage, treatment goals, and potential drug interactions. Always discuss options with your healthcare provider.</p>
            </div>
        </section>

    </main>

    <div class="email-capture" style="background: linear-gradient(135deg, #f0fdfa 0%, #f8fafc 100%); border: 1px solid #ccfbf1; border-radius: 12px; padding: 2rem; margin: 2rem 0; text-align: center;">
        <p style="font-family: 'Source Serif 4', Georgia, serif; font-size: 1.2rem; font-weight: 600; color: #0f172a; margin-bottom: 0.25rem;">Get evidence-based health updates</p>
        <p style="color: #64748b; font-size: 0.9rem; margin-bottom: 1rem;">No spam. Unsubscribe anytime.</p>
        <form class="email-form" style="display: flex; gap: 0.5rem; max-width: 420px; margin: 0 auto; flex-wrap: wrap; justify-content: center;" onsubmit="submitEmail(event)">
            <input type="email" name="email" placeholder="you@example.com" required style="flex: 1; min-width: 200px; padding: 0.6rem 1rem; border: 1px solid #d1d5db; border-radius: 8px; font-size: 0.95rem; outline: none;">
            <input type="hidden" name="source" value="glp1.md">
            <button type="submit" style="padding: 0.6rem 1.5rem; background: #0d9488; color: white; border: none; border-radius: 8px; font-size: 0.95rem; font-weight: 500; cursor: pointer;">Subscribe</button>
        </form>
        <p class="email-success" style="display: none; color: #0d9488; margin-top: 0.75rem; font-weight: 500;">‚úì You're in! Check your inbox.</p>
    </div>
    <script>
    function submitEmail(e) {
        e.preventDefault();
        const form = e.target;
        const data = new FormData(form);
        fetch('https://script.google.com/macros/s/AKfycbwUqO3zauyG_tuCZk0NALIDybayC7JhTbSm7RcQhivv6Lq0XCrQ8YgopTFqXjMSwt72/exec', {
            method: 'POST', body: data, mode: 'no-cors'
        }).then(() => {
            form.style.display = 'none';
            form.parentElement.querySelector('.email-success').style.display = 'block';
        });
    }
    </script>


    <footer>
        <div class="footer-inner">
            <p>¬© 2026 glp1.md ¬∑ Part of <a href="https://thrive.md" style="color: var(--accent); text-decoration: none;">thrive.md</a></p>
            <p style="margin-top: 8px; font-size: 12px;">Data from FDA-approved prescribing information and published clinical trials. This is not medical advice. Always consult your healthcare provider.</p>
        </div>
    </footer>
</body>
</html>
